S3258-119

What This Bill Does

The Senate-reported S.3258, titled the Aviation Medication Transparency Act of 2026, requires the Federal Aviation Administration to publish and maintain a public medication list within one year of enactment. It covers medications the FAA has determined may be safely prescribed or bought over the counter for relevant conditions and approved for medical certification or clearance of covered airmen and air traffic control specialists. The bill remains pending after its September 14, 2026 placement on the Senate calendar.

The operative reported substitute includes safety conditions consistent with the Guide for Aviation Medical Examiners or successor Federal Air Surgeon documents. For medical conditions affecting aviation duties or certificate privileges, the list must identify allowed prescription and over-the-counter medications, contraindications, and whether FAA review may be required. It must also include both Do Not Issue and Do Not Fly medications, be user-friendly and accessible, and be available on MedXPress when covered individuals first seek certification or clearance. It provides information about existing FAA permissions; it does not itself approve a drug or waive an individual's medical requirements.

Who Benefits and How

Airmen, air traffic control specialists and people training for those roles could find the relevant medication rules more easily and avoid some uncertainty and information-search costs. Doctors and other medical providers would receive an accessible means to contact the FAA about the list. Clear information on contraindications, review requirements and stabilization periods could assist discussions with aviation medical examiners, although a list cannot determine an individual's fitness for duty.

The FAA already publishes medication guidance, including over-the-counter tables and Do Not Issue/Do Not Fly material. The bill therefore creates a statutory compilation, dissemination and maintenance duty rather than the first public medication guidance. Its consultation process includes the Aeromedical Innovation and Modernization Working Group, airline-pilot bargaining organizations, FAA air-traffic-controller representatives, accredited aviation higher-education institutions, Part 141 professional flight schools, the Civil Aviation Medical Association, general-aviation operator and pilot organizations, and other participants chosen by the Administrator. Consultation provides input, not veto power or a promised federal payment.

Who Bears the Burden and How

FAA staff would have to compile and maintain the list, consult before dissemination, integrate its availability into MedXPress, and maintain provider contact information. No appropriation amount or dedicated staffing level is provided. The reported text requires minimum restricted-duty or no-duty stabilization periods when practicable, including for trainees. Unlike the introduced version, it does not require average periods and uses a practicability qualification.

The first update is due no later than one year after initial publication. Later updates are tied, as appropriate, to relevant changes in the medical-examiner guide or other FAA medical-certification policy. This replaces the introduced annual-update wording; it is not a requirement to republish every month merely because the Guide is described as monthly.

Applicants still face medical eligibility decisions and operational safety restrictions. Publication is expressly not to be construed as assigning liability to the FAA Administrator when someone relies on the list and suffers an adverse reaction, causes harm or injury, or is found ineligible for certification or clearance. This savings clause does not guarantee compensation, make every listed medication safe for every person, protect every private doctor or airline from liability, or create a new denial-appeal right. The analysis concerns the proposed information duties, not advice to take a particular medication.

Key Provisions

• Requires a public FAA list within one year, covering certification and clearance and making it available through MedXPress at the first application.
• Requires consultation and information about allowed medications, contraindications, possible FAA review, Do Not Issue/Do Not Fly restrictions, and provider contacts.
• Requires practicable minimum stabilization periods and updates linked to relevant policy changes; removes the introduced average-period and continuing annual-update wording.
• Preserves the rule that publication alone does not assign the Administrator liability for the specified reliance-related outcomes.